Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

NCT07695207 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

266

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

Interventions

DRUG: SMZ1
DRUG: SMZ1 Placebo

Sponsor

SANGMYUNG innovation